NASDAQ:AKTX Akari Therapeutics (AKTX) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free AKTX Stock Alerts $1.18 -0.01 (-0.84%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.17▼$1.2050-Day Range$1.16▼$2.3952-Week Range$1.08▼$5.50Volume10,002 shsAverage Volume12,153 shsMarket Capitalization$9.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Akari Therapeutics alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Akari Therapeutics Stock (NASDAQ:AKTX)Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Read More AKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKTX Stock News HeadlinesApril 26, 2024 | americanbankingnews.comAkari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Drop in Short InterestApril 24, 2024 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.comApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 16, 2024 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.comApril 15, 2024 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024April 15, 2024 | globenewswire.comAkari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024April 12, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday TradingApril 12, 2024 | msn.comDindin lethal in Akari’s disposal of Capital1April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 1, 2024 | finance.yahoo.comAkari Therapeutics Insider Ups Holding By 69% During YearApril 1, 2024 | globenewswire.comAkari Therapeutics Reports Full-Year 2023 Financial Results and Recent HighlightsMarch 17, 2024 | msn.comPVL: Fifi Sharma, Ced Domingo power Akari romp of NxledMarch 7, 2024 | bizjournals.comPetri Dish: C4’s deal with Merck KGaA; Boston and California biotechs mergeMarch 6, 2024 | stockhouse.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NSMarch 5, 2024 | businesswire.comAKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to ShareholdersFebruary 27, 2024 | msn.comPVL: Grethcel Soltones, Akari still a work in progressFebruary 25, 2024 | msn.comPVL: Ced Domingo has a quiet Akari debut as she adjusts to new systemFebruary 24, 2024 | msn.comPVL: Cignal turns back Akari to open All-Filipino bidFebruary 16, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday TradingFebruary 9, 2024 | msn.comPVL: Akari’s Max Juangco taking pressure of her pro debut in strideFebruary 7, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Slightly Lower in Wednesday TradingFebruary 2, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week HigherJanuary 23, 2024 | investing.comAkari Therapeutics PLC (AKTX)January 22, 2024 | msn.comPVL: Faith Nisperos, Akari Chargers aim for Final FourJanuary 2, 2024 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingJanuary 2, 2024 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement FinancingSee More Headlines Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2020Today4/26/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKTX CUSIPN/A CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.95 Quick Ratio0.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-39.40Miscellaneous Outstanding Shares7,920,000Free Float3,027,000Market Cap$9.36 million OptionableNot Optionable Beta0.96 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Rachelle Suzanne Jacques (Age 53)President, CEO & Director Comp: $632.25kMs. Wendy F. DiCicco CPA (Age 57)Interim Chief Financial Officer Comp: $540.34kMs. Melissa Bradford-Klug (Age 54)Chief Operating Officer Dr. Miles Nunn (Age 55)Chief Scientific Officer Dr. John F. Neylan III (Age 71)M.D., Executive VP & Chief Medical Officer Key CompetitorsAeterna ZentarisNASDAQ:AEZSAlterity TherapeuticsNASDAQ:ATHEElevai LabsNASDAQ:ELABMoleculin BiotechNASDAQ:MBRXGuardion Health SciencesNASDAQ:GHSIView All CompetitorsInstitutional OwnershipOmnia Family Wealth LLCBought 28,511 shares on 2/5/2024Ownership: 1.551%View All Institutional Transactions AKTX Stock Analysis - Frequently Asked Questions How have AKTX shares performed in 2024? Akari Therapeutics' stock was trading at $3.12 at the beginning of 2024. Since then, AKTX stock has decreased by 62.2% and is now trading at $1.18. View the best growth stocks for 2024 here. Are investors shorting Akari Therapeutics? Akari Therapeutics saw a decline in short interest in April. As of April 15th, there was short interest totaling 600 shares, a decline of 94.3% from the March 31st total of 10,500 shares. Based on an average daily trading volume, of 12,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company's shares are short sold. View Akari Therapeutics' Short Interest. When is Akari Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our AKTX earnings forecast. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics, Plc (NASDAQ:AKTX) released its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00. When did Akari Therapeutics' stock split? Akari Therapeutics's stock reverse split on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX). How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
